SCHEMBL3089252

SCHEMBL3089252

CCN(CC)C(=O)C(Cc1ccc(NC(=O)c2ccccc2NC(C)=O)cc1)C(=O)NS(=O)(=O)c1ccc2ccccc2c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1H4 Q96RI1 1/20 0.43
MAPT P10636 4/20 0.42
ALDH1A1 P00352 2/20 0.42
LARS1 Q9P2J5 1/20 0.41
NPC1 O15118 2/20 0.41
MEN1 O00255 2/20 0.41
HPGD P15428 2/20 0.41
KMT2A Q03164 2/20 0.41
HTT P42858 1/20 0.41
F2 P00734 3/20 0.40
ABCG2 Q9UNQ0 4/20 0.39
RAB9A P51151 1/20 0.39
KAT6A Q92794 2/20 0.39
PLA2G7 Q13093 2/20 0.38
KDM4E B2RXH2 1/20 0.38
LMNA P02545 1/20 0.38
GLA P06280 1/20 0.38
POLB P06746 1/20 0.38
GAA P10253 1/20 0.38
MAPK1 P28482 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3097268 0.92 LARS1 (0.42) NR1H4MAPTALDH1A1LARS1NPC1
SCHEMBL3090331 0.91 LARS1 (0.47) MAPTALDH1A1LARS1MEN1HPGD
SCHEMBL3100331 0.91 LARS1 (0.39) MAPTALDH1A1LARS1NPC1MEN1
SCHEMBL3086202 0.90 SMO (0.46) MAPTALDH1A1LARS1NPC1MEN1
SCHEMBL3093039 0.89 MEN1 (0.50) MAPTALDH1A1LARS1NPC1MEN1
SCHEMBL3093284 0.89 KAT6A (0.49) MAPTALDH1A1LARS1NPC1MEN1
SCHEMBL3096503 0.88 LARS1 (0.45) MAPTALDH1A1LARS1NPC1MEN1
SCHEMBL3101165 0.88 NPC1 (0.51) MAPTLARS1NPC1MEN1KMT2A
SCHEMBL15000205 0.88 MEN1 (0.46) NR1H4MAPTALDH1A1LARS1NPC1
SCHEMBL3100518 0.88 NPC1 (0.51) MAPTLARS1NPC1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2172450-B9 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORP (JP) 2014-10-08 EP disclosed
EP-2172450-B1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORP (JP) 2013-10-16 EP disclosed
US-8461209-B2 Malonic acid sulfonamide derivative and pharmaceutical use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2013-06-11 US disclosed
US-20100228026-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-09-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100228026-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF REN, AGTR2, AGTR1 NR1H4 211/4885MAPT 2813/4885ALDH1A1 617/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.